Vicki Chapman
Family · Mount Vernon, KYNPI 1356764468
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Dexcom, Inc. accounts for 62.1% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2021 at $21,064 and has fallen 68.1% since, to $6,724 in 2025. Among family clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 524 payments — averaging $108.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$35K
- Abbott$7K
- Xeris Pharmaceuticals, Inc.$5K
- Medtronic$3K
- Mannkind Corporation$2K
- Lilly USA, LLC$870
- plus $4K from 24 others
What the payments were for
- Consulting fees$8,31515%
- Speaking & faculty fees$30,82554%
- Travel & lodging$8,69115%
- Food & beverage$8,80016%
- Education$1080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 79 | $35,262 |
| Abbott | 53 | $7,191 |
| Xeris Pharmaceuticals, Inc. | 22 | $4,902 |
| Medtronic | 62 | $3,024 |
| Mannkind Corporation | 108 | $1,686 |
| Lilly USA, LLC | 44 | $870 |
| Novo Nordisk | 39 | $572 |
| RGH Enterprises LLC | 1 | $540 |
| Senseonics, Incorporated | 1 | $400 |
| Cequr Corporation | 2 | $381 |
| Boehringer Ingelheim | 21 | $340 |
| Corcept Therapeutics | 21 | $301 |
| Insulet Corporation | 14 | $295 |
| Sanofi-aventis U.S. LLC | 16 | $244 |
| Bayer | 5 | $98 |
| BETA Bionics, Inc. | 6 | $91 |
| Recordati_rare_diseases_inc. | 4 | $84 |
| Tandem Diabetes Care, Inc. | 4 | $77 |
| Ascensia Diabetes Care US Inc. | 3 | $67 |
| Merck | 4 | $62 |
| Boston Scientific | 2 | $37 |
| AbbVie | 2 | $36 |
| AstraZeneca | 2 | $33 |
| GSK | 2 | $32 |
| Catalyst Pharmaceuticals, Inc. | 1 | $25 |
| Amphastar Pharmaceuticals, Inc. | 1 | $19 |
| Zealand Pharma US, Inc. | 1 | $19 |
| Ascendis Pharma Endocrinology Inc | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Astellas Pharma US Inc | 2 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$27,808
- DEXCOM G7 GSS (161)$6,711
- FREESTYLE LIBRE 3$6,442
- GVOKE HYPOPEN$4,550
- MINIMED 780G$1,830
- Eversense$400
- CeQur Simplicity$300
- AFREZZA$143
How this compares
$56,738 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 280 | $343,327 |
| OzempicSemaglutide | 151 | $167,543 |
| JardianceEmpagliflozin | 98 | $95,071 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 88 | $90,120 |
| AfrezzaInsulin Regular, Human | 38 | $88,745 |
| JanuviaSitagliptin Phosphate | 45 | $45,220 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 17 | $37,697 |
| FarxigaDapagliflozin Propanediol | 48 | $36,755 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $26,998 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 40 | $26,854 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 22 | $26,107 |
| TrulicityDulaglutide | 20 | $25,596 |
| Gvoke Hypopen 2-PackGlucagon | 40 | $25,252 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 135 | $19,835 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $19,231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $870 | $391,980406 claims |
| Novo NordiskOzempic, Novolog | $572 | $183,898204 claims |
| Boehringer IngelheimJardiance | $340 | $95,07198 claims |
| Mannkind CorporationAfrezza | $1,686 | $88,74538 claims |
| MerckJanuvia | $62 | $45,22045 claims |
| AstraZenecaFarxiga | $33 | $36,75548 claims |
| AbbVieSynthroid | $36 | $3,54158 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.
Other family in Mount Vernon
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Carrie Parrish NyekanBowling Green$55K
- Alisha ClemonsLexington$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.